[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 962 Introduced in Senate (IS)]

<DOC>






117th CONGRESS
  1st Session
                                 S. 962

To prioritize funding for an expanded and sustained national investment 
                        in biomedical research.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             March 24, 2021

 Mr. Durbin (for himself, Mr. Van Hollen, Ms. Baldwin, Mr. Brown, Mr. 
  Cardin, Mr. Blumenthal, and Ms. Klobuchar) introduced the following 
      bill; which was read twice and referred to the Committee on 
                             Appropriations

_______________________________________________________________________

                                 A BILL


 
To prioritize funding for an expanded and sustained national investment 
                        in biomedical research.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``American Cures Act''.

SEC. 2. APPROPRIATIONS FOR INNOVATION.

    (a) In General.--There are hereby authorized to be appropriated, 
and appropriated, out of any monies in the Treasury not otherwise 
appropriated, the following:
            (1) National institutes of health.--For the National 
        Institutes of Health at the Department of Health and Human 
        Services--
                    (A) for fiscal year 2022, $45,903,000,000;
                    (B) for fiscal year 2023, $49,116,000,000;
                    (C) for fiscal year 2024, $52,554,000,000;
                    (D) for fiscal year 2025, $56,233,000,000;
                    (E) for fiscal year 2026, $60,169,000,000;
                    (F) for fiscal year 2027, $64,380,000,000;
                    (G) for fiscal year 2028, $68,890,000,000;
                    (H) for fiscal year 2029, $73,710,000,000;
                    (I) for fiscal year 2030, $78,870,000,000;
                    (J) for fiscal year 2031, $84,390,000,000; and
                    (K) for fiscal year 2032 and each fiscal year 
                thereafter, the amount appropriated under this 
                paragraph for the previous fiscal year, increased by 
                the percentage increase (if any), during the previous 
                fiscal year, in the Consumer Price Index for all urban 
                consumers published by the Bureau of Labor Statistics.
            (2) Centers for disease control and prevention.--For the 
        Centers for Disease Control and Prevention at the Department of 
        Health and Human Services--
                    (A) for fiscal year 2022, $8,453,000,000;
                    (B) for fiscal year 2023, $9,044,000,000;
                    (C) for fiscal year 2024, $9,667,000,000;
                    (D) for fiscal year 2025, $10,354,000,000;
                    (E) for fiscal year 2026, $11,079,000,000;
                    (F) for fiscal year 2027, $11,850,000,000;
                    (G) for fiscal year 2028, $12,680,000,000;
                    (H) for fiscal year 2029, $13,570,000,000;
                    (I) for fiscal year 2030, $14,520,000,000;
                    (J) for fiscal year 2031, $15,540,000,000; and
                    (K) for fiscal year 2032 and each fiscal year 
                thereafter, the amount appropriated under this 
                paragraph for the previous fiscal year, increased by 
                the percentage increase (if any), during the previous 
                fiscal year, in the Consumer Price Index for all urban 
                consumers published by the Bureau of Labor Statistics.
            (3) Research, development, test, and evaluation program of 
        the department of defense health program.--For the research, 
        development, test, and evaluation program of the Department of 
        Defense health program--
                    (A) for fiscal year 2022, $2,890,000,000;
                    (B) for fiscal year 2023, $3,090,000,000;
                    (C) for fiscal year 2024, $3,310,000,000;
                    (D) for fiscal year 2025, $3,540,000,000;
                    (E) for fiscal year 2026, $3,790,000,000;
                    (F) for fiscal year 2027, $4,060,000,000;
                    (G) for fiscal year 2028, $4,340,000,000;
                    (H) for fiscal year 2029, $4,640,000,000;
                    (I) for fiscal year 2030, $4,970,000,000;
                    (J) for fiscal year 2031, $5,320,000,000; and
                    (K) for fiscal year 2032 and each fiscal year 
                thereafter, the amount appropriated under this 
                paragraph for the previous fiscal year, increased by 
                the percentage increase (if any), during the previous 
                fiscal year, in the Consumer Price Index for all urban 
                consumers published by the Bureau of Labor Statistics.
            (4) Medical and prosthetics research program of the 
        department of veterans affairs.--For the medical and 
        prosthetics research program of the Department of Veterans 
        Affairs--
                    (A) for fiscal year 2022, $872,000,000;
                    (B) for fiscal year 2023, $933,000,000;
                    (C) for fiscal year 2024, $998,000,000;
                    (D) for fiscal year 2025, $1,070,000,000;
                    (E) for fiscal year 2026, $1,140,000,000;
                    (F) for fiscal year 2027, $1,220,000,000;
                    (G) for fiscal year 2028, $1,310,000,000;
                    (H) for fiscal year 2029, $1,400,000,000;
                    (I) for fiscal year 2030, $1,500,000,000;
                    (J) for fiscal year 2031, $1,600,000,000; and
                    (K) for fiscal year 2032 and each fiscal year 
                thereafter, the amount appropriated under this 
                paragraph for the previous fiscal year, increased by 
                the percentage increase (if any), during the previous 
                fiscal year, in the Consumer Price Index for all urban 
                consumers published by the Bureau of Labor Statistics.
    (b) Availability.--Amounts appropriated under subsection (a) shall 
remain available until expended.
    (c) Definitions.--In this section:
            (1) Centers for disease control and prevention.--The term 
        ``Centers for Disease Control and Prevention'' means the 
        appropriations accounts that support the various institutes, 
        offices, and centers that make up the Centers for Disease 
        Control and Prevention.
            (2) Research, development, test, and evaluation program of 
        the department of defense health program.--The term ``research, 
        development, test, and evaluation program of the Department of 
        Defense health program'' means the appropriations accounts that 
        support the various institutes, offices, and centers that make 
        up the research, development, test, and evaluation program of 
        the Department of Defense health program.
            (3) Medical and prosthetics research program of the 
        department of veterans affairs.--The term ``medical and 
        prosthetics research program of the Department of Veterans 
        Affairs'' means the appropriations accounts that support the 
        various institutes, offices, and centers that make up the 
        medical and prosthetics research program of the Department of 
        Veterans Affairs.
            (4) National institutes of health.--The term ``National 
        Institutes of Health'' means the appropriations accounts that 
        support the various institutes, offices, and centers that make 
        up the National Institutes of Health.
    (d) Exemption of Certain Appropriations From Sequestration.--
            (1) In general.--Section 255(g)(1)(A) of the Balanced 
        Budget and Emergency Deficit Control Act (2 U.S.C. 
        905(g)(1)(A)) is amended by inserting after ``Advances to the 
        Unemployment Trust Fund and Other Funds (16-0327-0-1-600).'' 
        the following:
                            ``Appropriations under the American Cures 
                        Act.''.
            (2) Applicability.--The amendment made by this section 
        shall apply to any sequestration order issued under the 
        Balanced Budget and Emergency Deficit Control Act of 1985 (2 
        U.S.C. 900 et seq.) on or after the date of enactment of this 
        Act.
    (e) Budgetary Effects.--
            (1) Statutory paygo scorecards.--The budgetary effects of 
        this section shall not be entered on either PAYGO scorecard 
        maintained pursuant to section 4(d) of the Statutory Pay-As-
        You-Go Act of 2010 (2 U.S.C. 933(d)).
            (2) Senate paygo scorecards.--The budgetary effects of this 
        section shall not be entered on any PAYGO scorecard maintained 
        for purposes of section 4106 of H. Con. Res. 71 (115th 
        Congress).
                                 <all>